ClinicalTrials.gg
CompletedNCT03392441Updated Feb 3, 2022

Insulin Deprivation on Brain Structure and Function in Humans With Type 1 Diabetes

An interventional study of Insulin Deprivation in Type 1 Diabetic Patients in Diabetes Mellitus, Type 1, Diabetes and Diabetes Complications, sponsored by Mayo Clinic. Completed at 1 site in United States. Open to participants aged 14 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-03.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
14 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-13

Among 16 studies in Diabetes Mellitus, Type 1 by Mayo Clinic — 3 open to participants now, 3 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Mayo Clinic.

Enrollment
5th of 14
28 · median 17
Started
2017
the only one that year
No phase
8 of 16
2 open now
Registered
6th of 16
by date

Among the 16 studies in Diabetes Mellitus, Type 1 by Mayo Clinic, this one is the 5th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2017, is one of 8 with no phase, and was the 6th registered.

Diabetes Mellitus, Type 1

3,754 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

3 of the 16 studies in Diabetes Mellitus, Type 1 by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 14 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Diabetes Mellitus, Type 1 by Mayo Clinic, or all of them as a file.
02

Study summary

What are the effects of transient insulin deprivation on brain structure, blood flow, mitochondrial function, and cognitive function in T1DM patients?

What are the effects of transient insulin deprivation on circulating exosomes and metabolites in T1DM patients?

Read the detailed description

Diabetes is associated with impaired cognition, abnormal brain development in children, and dementia in older adults, however the underlying mechanisms remain unclear. Little is known about the brain-specific effects of acute insulin deficiency. Our recent studies in diabetic mice show an overall down regulation of brain mitochondrial ATP production and up regulation of several key mitochondrial proteins, indicating that insulin withdrawal has a profound effect on brain mitochondria as well as proteins implicated in neurodegeneration. Hyperglycemia is known to alter cognitive function, but it is unclear if insulin deprivation independently alters cognitive function and has not been assessed in humans.

In order to investigate the effects of insulin deprivation on the human brain, we propose a study involving temporary insulin deprivation in adolescents and adults with type 1 diabetes (T1DM). We will perform brain MRI, phosphorus31 spectroscopy, cognitive testing, circulating blood exosome measurements, and proteomics from muscle biopsy; comparing these measures during insulin treatment and deprivation between diabetic patients and age-, sex-, BMI-matched controls.

Specific aim 1: Determine whether transient insulin deprivation in T1DM adults and adolescents alters brain structure, functions and blood flow as assessed by structural/functional MRI.

Specific aim 2: Determine whether transient insulin deprivation in T1DM adults and adolescents alters cognitive function.

Specific aim 3: Determine whether transient insulin deprivation in T1DM adults and adolescents alters the circulating blood exosome contents and metabolome that can potentially impact brain functions.

Specific aim 4: Determine whether transient insulin deprivation in T1DM adults alters the skeletal muscle proteome homeostasis especially those involved in fission and fusion

03

Conditions studied

  • Diabetes Mellitus, Type 1
  • Diabetes
  • Diabetes Complications

Keywords

  • dementia
  • cognition
  • insulin
  • adolescent
04

Who can participate

Ages eligible
14 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and females age 14-17 years, females must be post-menarcheal
  • Age 18-45 years
  • Able to provide written consent
  • Parents able to provide written consent
  • T1DM treated with CSII or MDI (not degludec)

Exclusion criteria

Exclusion criteria:

  • \< 20 or > 30 kg/m2
  • BMI z-score \<5th or >95th percentile
  • Celiac disease
  • Pregnancy
  • Smoking
  • Reported history of illicit substance use
  • History of active cardiovascular, cerebrovascular, or peripheral vascular disease
  • Active renal disease evidenced by estimated \< 50 mL/min/1.73 m2
  • History of traumatic brain injury
  • Dementia or any other neurologic disease
  • Psychiatric disease\
  • Any learning disability
  • > 8.5%
  • Hemoglobin A1c > 9%
  • T2DM, or impaired fasting glucose
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Insulin Deprivation

    Insulin Deprivation in Type 1 Diabetic Patients will be performed for a short time period (4-6 hours). Changes to Age, Sex, and Gender matched controls will be compared.

    Other: Insulin Deprivation in Type 1 Diabetic Patients

Interventions

  • OtherInsulin Deprivation in Type 1 Diabetic Patients

    Type 1 Diabetic Patients requiring insulin will have insulin stopped for a short period of time (4-6 hours)

06

What researchers measure

Primary outcomes

  1. Change in Structural MRI

    Structural magnetic resonance imaging (MRI) is a non-invasive technique for examining the anatomy and pathology of the brain (as opposed to using functional magnetic resonance imaging \[fMRI\] to examine brain activity. This produces images which can be used for clinical radiological reporting as well as for detailed analysis.

    Time frame: baseline, 6 hours

07

Study locations

1 site
  • Mayo Clinic in Rochester
    Rochester, Minnesota 55905, United States
08

References and documents

Publications

  • Creo AL, Cortes TM, Jo HJ, Huebner AR, Dasari S, Tillema JM, Lteif AN, Klaus KA, Ruegsegger GN, Kudva YC, Petersen RC, Port JD, Nair KS. Brain functions and cognition on transient insulin deprivation in type 1 diabetes. JCI Insight. 2021 Mar 8;6(5):e144014. doi: 10.1172/jci.insight.144014. PubMed 33561011 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Aug 2018, 8 months.

Of 845 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's 8 months is below that.

Counting every sponsor, half of 950 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2017
First posted
Jan 8, 2018
StartActual
Nov 30, 2017
Primary completionActual
Aug 1, 2018
CompletionActual
Jul 5, 2019
Last update
Feb 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03392441
Lead sponsor
Mayo Clinic
Responsible party
K. Sreekumaran Nair (Consultant Endocrinology and Metabolism, Mayo Clinic) — Principal investigator
First posted
Jan 8, 2018
Start date
Nov 30, 2017
Primary completion
Aug 1, 2018
Completion
Jul 5, 2019
Last update
Feb 3, 2022

Study contacts

K Sreekumaran Nair
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion